These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36064378)

  • 1. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Done N; Petigara T; Mohanty S; Song Y; Liu Q; Lemus-Wirtz E; Signorovitch J; Sarpong E; Weiss T
    BMC Infect Dis; 2022 Mar; 22(1):294. PubMed ID: 35346092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis.
    Hu T; Sarpong EM; Song Y; Done N; Liu Q; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    Pneumonia (Nathan); 2023 Apr; 15(1):8. PubMed ID: 37016411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019.
    Mohanty S; Done N; Liu Q; Song Y; Wang T; Gaburo K; Sarpong EM; White M; Weaver JP; Signorovitch J; Weiss T
    Vaccine; 2024 Apr; 42(11):2758-2769. PubMed ID: 38485640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018.
    Hu T; Song Y; Done N; Mohanty S; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Weiss T
    BMC Health Serv Res; 2023 Apr; 23(1):398. PubMed ID: 37098521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
    Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
    Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England.
    Mohanty S; Podmore B; Cuñado Moral A; Weiss T; Matthews I; Sarpong E; Méndez I; Qizilbash N
    BMC Public Health; 2023 Jan; 23(1):201. PubMed ID: 36717794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
    Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.
    Mohanty S; Hu T; Yang G; Khan TK; Owusu-Edusei K; Sukarom I
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046433. PubMed ID: 35420975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R; Taylor T; Moore MR;
    Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction.
    Glikman D; Dagan R; Barkai G; Averbuch D; Guri A; Givon-Lavi N; Ben-Shimol S;
    Pediatr Infect Dis J; 2018 Oct; 37(10):1048-1053. PubMed ID: 29750768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
    Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
    Yildirim I; Lapidot R; Shaik-Dasthagirisaheb YB; Hinderstein S; Lee H; Klevens M; Grant L; Arguedas Mohs AG; Cane A; Madoff L; Johnson H; Ivanof C; Burns M; Pelton S
    Pediatrics; 2024 Jan; 153(1):. PubMed ID: 38087952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.